glycoprotein-e2--hepatitis-c-virus and Pneumonia--Viral

COVID-19, is a disease resulting from the SARS-CoV-2 global pandemic. Due to the current global emergency and the length of time required to develop specific antiviral agent(s) and a vaccine for SARS-CoV-2, the world health organization (WHO) adopted the strategy of repurposing existing medications to treat COVID-19. Iron oxide nanoparticles (IONPs) were previously approved by the US food and drug administration (FDA) for anemia treatment and studies have also demonstrated its antiviral activity in vitro. Therefore, we performed a docking study to explore the interaction of IONPs (Fe

Topics: Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Ferric Compounds; Humans; Metal Nanoparticles; Molecular Docking Simulation; Pandemics; Pneumonia, Viral; Protein Conformation; Spike Glycoprotein, Coronavirus; United States; United States Food and Drug Administration; Viral Envelope Proteins